Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2023-09-06 Purchase | 2023-09-07 4:16 pm | Aclaris Therapeutics Inc. | ACRS | Balthaser Kevin Chief Financial Officer | 9,490 | $7.9 | $74,971 | 15,461 (Direct) | View |
| 2023-03-02 Sale | 2023-03-03 8:09 pm | Aclaris Therapeutics Inc. | ACRS | Balthaser Kevin Chief Financial Officer | 1,894 | $12.45 | $23,579 | 16,081 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-09-01 Tax Withholding | 2024-09-04 7:52 pm | N/A N/A | Aclaris Therapeutics Inc. | ACRS | Balthaser Kevin Chief Financial Officer | 286 | $1.18 | 24,697 (Direct) | View |
| 2024-09-01 Exercise | 2024-09-04 7:52 pm | N/A N/A | Aclaris Therapeutics Inc. | ACRS | Balthaser Kevin Chief Financial Officer | 1,000 | $0 | 24,697 (Direct) | View |
| 2024-03-01 Tax Withholding | 2024-03-05 5:02 pm | N/A N/A | Aclaris Therapeutics Inc. | ACRS | Balthaser Kevin Chief Financial Officer | 1,417 | $1.24 | 29,833 (Direct) | View |
| 2024-03-01 Exercise | 2024-03-05 5:02 pm | N/A N/A | Aclaris Therapeutics Inc. | ACRS | Balthaser Kevin Chief Financial Officer | 4,975 | $0 | 29,833 (Direct) | View |
| 2024-02-01 Option Award | 2024-02-05 7:27 pm | N/A 2034-01-31 | Aclaris Therapeutics Inc. | ACRS | Balthaser Kevin Chief Financial Officer | 413,000 | $0 | 413,000 (Direct) | View |
| 2024-01-01 Tax Withholding | 2024-01-03 4:47 pm | N/A N/A | Aclaris Therapeutics Inc. | ACRS | Balthaser Kevin Chief Financial Officer | 2,536 | $1.05 | 42,925 (Direct) | View |
| 2024-01-01 Exercise | 2024-01-03 4:47 pm | N/A N/A | Aclaris Therapeutics Inc. | ACRS | Balthaser Kevin Chief Financial Officer | 7,500 | $0 | 42,925 (Direct) | View |
| 2023-09-01 Tax Withholding | 2023-09-05 5:08 pm | N/A N/A | Aclaris Therapeutics Inc. | ACRS | Balthaser Kevin Chief Financial Officer | 285 | $7.9 | 6,971 (Direct) | View |
| 2023-09-01 Exercise | 2023-09-05 5:08 pm | N/A N/A | Aclaris Therapeutics Inc. | ACRS | Balthaser Kevin Chief Financial Officer | 1,000 | $0 | 6,971 (Direct) | View |
| 2023-03-01 Exercise | 2023-03-03 8:09 pm | N/A N/A | Aclaris Therapeutics Inc. | ACRS | Balthaser Kevin Chief Financial Officer | 6,450 | $0 | 16,081 (Direct) | View |
| 2023-02-01 Option Award | 2023-02-03 4:55 pm | N/A 2033-01-31 | Aclaris Therapeutics Inc. | ACRS | Balthaser Kevin Chief Financial Officer | 135,000 | $0 | 135,000 (Direct) | View |
Ownership | 2023-01-06 4:31 pm | N/A N/A | Aclaris Therapeutics Inc. | ACRS | Balthaser Kevin Chief Financial Officer | 0 | $0 | 82,175 (Direct) | View |